血液科学(英文)最新文献_第2页

Novel heterozygous mutations of TNFRSF13B in EBV-associated T/NK lymphoproliferative diseases (EBV-T/NK-LPDs). EBV相关T/NK淋巴细胞增生性疾病（EBV-T/NK-LPDs）中TNFRSF13B的新型杂合突变。

血液科学(英文) Pub Date : 2024-01-15 eCollection Date: 2024-01-01 DOI: 10.1097/BS9.0000000000000180

Xinyue Deng, Tong Ge, Kefeng Shen, Jiachen Wang, Wei Mu, Hui Luo, Jia Gu, Meilan Zhang, Min Xiao

引用次数: 0

Acupoint transplantation versus non-acupoint transplantation using autologous peripheral blood mononuclear cells in treating peripheral arterial disease. 使用自体外周血单核细胞治疗外周动脉疾病的穴位移植与非穴位移植。

血液科学(英文) Pub Date : 2024-01-15 eCollection Date: 2024-01-01 DOI: 10.1097/BS9.0000000000000175

Wenjing Guo, Ling Pan, Ruiyu Yang, Jiali Sun, Qinglin Hu, Pingping Huang

{"title":"Acupoint transplantation versus non-acupoint transplantation using autologous peripheral blood mononuclear cells in treating peripheral arterial disease.","authors":"Wenjing Guo, Ling Pan, Ruiyu Yang, Jiali Sun, Qinglin Hu, Pingping Huang","doi":"10.1097/BS9.0000000000000175","DOIUrl":"10.1097/BS9.0000000000000175","url":null,"abstract":"Numerous studies have discussed the therapeutic outcomes of using cell therapy or acupuncture to treat peripheral artery disease (PAD). However, there are no long-term studies on the safety and efficacy of transplanting peripheral blood mononuclear cells (PBMNCs) via acupoints to treat PAD. We first reviewed the short-term and long-term clinical results of PAD patients treated with PBMNCs through intramuscular non-acupoint transplantation (control group; n = 45) or intramuscular acupoint transplantation (acupoint group; n = 45) at a single university hospital general medical center between December 2002 and September 2022. Pain intensity (assessed with the verbal rating scale [VRS] score) in the acupoint group was considerably lower than that in the control group at month 1 (mean ± standard deviation [SD]: 1.29 ± 0.96 vs 1.76 ± 0.82; P = 0.016) and month 3 (mean ± SD: 1.27 ± 0.90 vs 1.61 ± 0.86; P = 0.042). We observed significant improvement of VRS score (P < .001 for all) and ankle-brachial index (ABI; P < .001 for all) from baseline in both groups at months 1, 3, 6, 12, 36, and 60. The 10-year cumulative rate of major amputation-free survival (MAFS) was higher in the acupoint group as compared to the control group (81.9%, 95% confidence interval [CI]: 71.3%-94.1% vs 78.5%, 95% CI: 66.7%-92.3%; P = 0.768). Compared with the routine injection method, intramuscular transplantation of PBMNCs via selected acupoints could significantly decrease the short-term pain intensity in patients with PAD, which remains an option for consideration.","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10789451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139473104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sequential infusion of two different chimeric antigen receptor T cells: induction of a deep and durable remission. 连续输注两种不同的嵌合抗原受体 T 细胞：诱导深度和持久缓解。

血液科学(英文) Pub Date : 2024-01-10 eCollection Date: 2024-01-01 DOI: 10.1097/BS9.0000000000000177

Kailin Xu

引用次数: 0

Hematopoietic stem cell heterogeneity in non-human primates revealed by five-lineage output bias analysis. 通过五系输出偏差分析揭示非人灵长类的造血干细胞异质性。

血液科学(英文) Pub Date : 2024-01-10 eCollection Date: 2024-01-01 DOI: 10.1097/BS9.0000000000000176

Man Zhang, Di Liu, Yu Lan, Bing Liu, Zongcheng Li, Yanli Ni

{"title":"Hematopoietic stem cell heterogeneity in non-human primates revealed by five-lineage output bias analysis.","authors":"Man Zhang, Di Liu, Yu Lan, Bing Liu, Zongcheng Li, Yanli Ni","doi":"10.1097/BS9.0000000000000176","DOIUrl":"10.1097/BS9.0000000000000176","url":null,"abstract":"Understanding hematopoietic stem cell (HSC) heterogeneity is crucial for treating malignant blood disorders. Compared with mice, we have limited knowledge of the heterogeneity of human HSCs. Fortunately, non-human primates (NHPs) have become the best animal models for studying human HSCs. Here, we employed a public dataset derived from NHP autologous bone marrow transplantation, and focused on a total of 820 HSC clones with reconstitution capacity of all available five lineages (granulocyte, monocyte, B cell, T cell, and natural killer cell) at two time points (11/12 and/or 42/43 months). Intriguingly, unsupervised clustering on these clones revealed six HSC subtypes, including a lymphoid/myeloid balanced (LM-balanced) subtype and five single-lineage-biased subtypes. We also observed that the subtypes of these HSC clones might change over time, and a given subtype could transition into any one of the other five subtypes, albeit with a certain degree of selectivity. Particularly, each of the six subtypes was more likely to turn into lymphoid-biased rather than myeloid-biased ones. Additionally, our five-lineage classification method exhibited strong correlation with traditional lymphoid/myeloid bias classification method. Specifically, our granulocyte- and monocyte-biased subtypes were predominantly attributed to α-HSCs, while LM-balanced, B cell-biased, and T cell-biased subtypes were primarily associated with β-HSCs. The γ-HSCs were composed of a small subset of B cell-biased and T cell-biased subtypes. In summary, our five-lineage classification identifies more finely tuned HSC subtypes based on lineage output bias. These findings enrich our understanding of HSC heterogeneity in NHPs and provide important insights for human research.","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10781131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139426188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation. 造血干细胞移植后预防巨细胞病毒感染的勒替莫韦的有效性和安全性。

血液科学(英文) Pub Date : 2024-01-10 eCollection Date: 2024-01-01 DOI: 10.1097/BS9.0000000000000178

Wen-Wen Li, Yong-Mei Zhang, Meng-Zhu Shen, Xiao-Dong Mo

{"title":"Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation.","authors":"Wen-Wen Li, Yong-Mei Zhang, Meng-Zhu Shen, Xiao-Dong Mo","doi":"10.1097/BS9.0000000000000178","DOIUrl":"10.1097/BS9.0000000000000178","url":null,"abstract":"Letermovir is a specific inhibitor of cytomegalovirus (CMV) terminase complex. Several studies have reported that letermovir can effectively prevent CMV activation after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We aimed to identify the efficacy and safety of letermovir prophylaxis for CMV infection after allo-HSCT with a systemic review and meta-analysis. A literature search was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. PubMed and Embase databases were searched. A total of 28 studies were included. The incidence of CMV activation at 14 weeks after HSCT was 0.10 (95% confidence interval [CI], 0.06-0.18), which was 0.10 (95% CI, 0.04-0.21) and 0% in adult and children (2 studies were included and both of them were 0%). In addition, the incidence of CMV activation at 14 weeks after allo-HSCT was 0.11 (95% CI, 0.06-0.21) and 0.07 (only 1 study included), respectively, in retrospective and prospective studies. The incidence of CMV activation at 100 and 200 days after HSCT was 0.23 (95% CI, 0.16-0.33) and 0.49 (95% CI, 0.32-0.67), respectively. The incidence of CMV disease at 14 weeks and at 6 months after HSCT was 0.01 (95% CI, 0.01-0.02) and 0.03 (95% CI, 0.01-0.09), respectively. Thus, our systemic review and meta-analysis suggested that letermovir prophylaxis was safe and effective for CMV activation after allo-HSCT.","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10781138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139426187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Essential procedures of single-cell RNA sequencing in multiple myeloma and its translational value. 多发性骨髓瘤单细胞RNA测序的基本程序及其翻译价值。

血液科学(英文) Pub Date : 2023-11-02 eCollection Date: 2023-10-01 DOI: 10.1097/BS9.0000000000000172

Jun Du, Xiao-Ran Gu, Xiao-Xiao Yu, Yang-Jia Cao, Jian Hou

{"title":"Essential procedures of single-cell RNA sequencing in multiple myeloma and its translational value.","authors":"Jun Du, Xiao-Ran Gu, Xiao-Xiao Yu, Yang-Jia Cao, Jian Hou","doi":"10.1097/BS9.0000000000000172","DOIUrl":"10.1097/BS9.0000000000000172","url":null,"abstract":"Multiple myeloma (MM) is a malignant neoplasm characterized by clonal proliferation of abnormal plasma cells. In many countries, it ranks as the second most prevalent malignant neoplasm of the hematopoietic system. Although treatment methods for MM have been continuously improved and the survival of patients has been dramatically prolonged, MM remains an incurable disease with a high probability of recurrence. As such, there are still many challenges to be addressed. One promising approach is single-cell RNA sequencing (scRNA-seq), which can elucidate the transcriptome heterogeneity of individual cells and reveal previously unknown cell types or states in complex tissues. In this review, we outlined the experimental workflow of scRNA-seq in MM, listed some commonly used scRNA-seq platforms and analytical tools. In addition, with the advent of scRNA-seq, many studies have made new progress in the key molecular mechanisms during MM clonal evolution, cell interactions and molecular regulation in the microenvironment, and drug resistance mechanisms in target therapy. We summarized the main findings and sequencing platforms for applying scRNA-seq to MM research and proposed broad directions for targeted therapies based on these findings.","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71524095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute intestinal GVHD following donor-derived CD7-CAR-T-cell infusion in a child with Omicron COVID-19. 一名患有奥密克戎新冠肺炎的儿童输注供体来源的CD7-CAR-T-细胞后急性肠道GVHD。

血液科学(英文) Pub Date : 2023-11-02 eCollection Date: 2023-10-01 DOI: 10.1097/BS9.0000000000000170

Yu Lian, Zhilin Gao, Juanjuan Ti, Zhuanzhuan Yu, Liangming Ma, Jia Wei

引用次数: 0

Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation presenting as pericardial effusion. 异基因造血干细胞移植后急性髓系白血病复发，表现为心包积液。

血液科学(英文) Pub Date : 2023-11-02 eCollection Date: 2023-10-01 DOI: 10.1097/BS9.0000000000000174

Yuyan Shen, Jiali Sun, Donglin Yang, Sizhou Feng

引用次数: 0

CAR-T cell therapy: Where are we now, and where are we heading? CAR-T细胞治疗：我们现在在哪里，我们将走向何方？

血液科学(英文) Pub Date : 2023-11-02 eCollection Date: 2023-10-01 DOI: 10.1097/BS9.0000000000000173

Jia-Yi Wang, Liang Wang

引用次数: 0

The opposite impact of Janus kinase inhibitor Ruxolitinib on the function of bone marrow mesenchymal stem cells and immune cells in acute GVHD recipients. Janus激酶抑制剂Ruxolitinib对急性移植物抗宿主病受者骨髓间充质干细胞和免疫细胞功能的相反影响。

血液科学(英文) Pub Date : 2023-09-08 eCollection Date: 2023-10-01 DOI: 10.1097/BS9.0000000000000171

Defu Zeng

引用次数: 0